Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Tachycardia, Atrioventricular Nodal Reentry
Interventions
Cardiac Invasive Electrophysiological Study
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
16 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions
Etripamil, Placebo
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
Interventions
Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Orlando, Florida • Overland Park, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Interventions
Prospective observational cohorts
Other
Lead sponsor
Edgar Jaeggi
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Oak Lawn, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Little Rock, Arkansas • Vista, California • West Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Atrial Fibrillation
Interventions
Atrial fibrillation ablation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions
Not listed
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
Not listed
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia, Arrhythmias, Cardiac, Atrial Flutter, Atrial Fibrillation, Paroxysmal or Persistent, Atrial Arrhythmia, Atrial Tachycardia
Interventions
Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
Device
Lead sponsor
Cortex
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced May 22, 2026, 12:00 AM EDT
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Gilbert, Arizona • Fremont, California • Stanford, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced May 22, 2026, 12:00 AM EDT